FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567705467> ?p ?o ?g. }

• W2567705467 abstract "Abstract Chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy characterized by defects in both cellular and humoral immunity. Each immune defect can be linked to common infectious complications affecting these patients. Predisposition to infections can be compounded by immunosuppression from cytotoxic chemotherapy. The purine analog fludarabine has been associated with a spectrum of infections caused by prolonged T lymphocyte depletion. The combination of fludarabine, cyclophosphamide, and rituximab (FCR) was developed based on complementary activity of the combination. FCR has significant activity in both chemotherapy-naïve (ChN) and previously treated (PrT) patients with CLL. We analyzed risk factors for infection and describe the infections experienced by both ChN and PrT patients during FCR treatment. We performed a retrospective review of medical records of 224 ChN and 177 PrT patients with CLL treated with the FCR regimen at MD Anderson Cancer Center from 7/99-8/02. Review was until relapse, death, or end of treatment. We focused on infectious events that occurred during and within 30 days of the last cycle of FCR treatment. Prophylaxis for herpes virus (valacyclovir) was recommended for all patients. Prophylaxis for P carinii (trimethoprim-sulfa) was recommended for all PrT patients and was done at the discretion of the treating physician for ChN patients. Infectious events were experienced by 96/224 (43.2%) ChN and 99/177 (56.2%) PrT patients. Causative agents were identified in 23% of events for ChN and 17% of events for the PrT patients (Table 1). There was a higher incidence of any event (p=0.012) and major infectious (MI) events (p&lt;0.001) in PrT versus ChN patients. Major infections included pneumonia, sepsis and fever of unknown origin. Among ChN patients, univariate analysis identified low serum IgG (&lt;700 mg/dL) (p=0.04), increased WBC count (p=0.049), and &gt;2 chemotherapy courses (p=0.044) as risk factors for MI. Multivariate analysis identified low serum IgG (p=0.03) as the only predictor for MI. Among PrT patients, univariate analysis identified female gender (p=0.015) and baseline hemoglobin level (p=0.031) as risk factors for MI. Multivariate analysis identified increased WBC count (p=0.026) and high (&gt;4.0 mg/dL) beta-2 microglobulin (ß2M) (p=0.027) as risk factors for MI in PrT patients. Among ChN and PrT patients none of the variables were found to be risk factor for minor infections (mI) in univariate analysis; multivariate analysis identified high ß2M (p=0.034) and splenomegaly (p=0.033) as significant predictors for occurrence of mI among PrT patients. For ChN patients, the nadir neutrophil count was not significantly associated with occurrence of mI or MI over the 6 courses of treatment. On the contrary, it was associated with occurrence of minor, major and any infection in the PrT patients. FCR is a higly effective and well-tolerated regimen. IgG &lt;700 mg/dL was the main predictive variable for MI in ChN patients; baseline WBC count and ß2M &gt;4.0 mg/L were the main predictive variables for MI in PrT patients. Table 1 Confirmed Infectious agent ChN Events/224 Pts PrT Events/177/Pts Gram+ bacteria 1 4 Gram- bacteria 4 1 Candida species 1 0 Aspergillus species 2 1 Pneumocystis carinii 2 0 VZV 3 6 HSV 6 4 CMV 3 1" @default.
• W2567705467 created "2017-01-06" @default.
• W2567705467 creator A5006104041 @default.
• W2567705467 creator A5016966610 @default.
• W2567705467 creator A5027575595 @default.
• W2567705467 creator A5028845635 @default.
• W2567705467 creator A5035354255 @default.
• W2567705467 creator A5046097970 @default.
• W2567705467 creator A5069999714 @default.
• W2567705467 creator A5089428686 @default.
• W2567705467 creator A5090435894 @default.
• W2567705467 date "2005-11-16" @default.
• W2567705467 modified "2023-10-12" @default.
• W2567705467 title "Infections in Patients with Chronic Lymphocytic Leukemia Treated with Chemoimmunotherapy." @default.
• W2567705467 doi "https://doi.org/10.1182/blood.v106.11.720.720" @default.
• W2567705467 hasPublicationYear "2005" @default.
• W2567705467 type Work @default.
• W2567705467 sameAs 2567705467 @default.
• W2567705467 citedByCount "2" @default.
• W2567705467 crossrefType "journal-article" @default.
• W2567705467 hasAuthorship W2567705467A5006104041 @default.
• W2567705467 hasAuthorship W2567705467A5016966610 @default.
• W2567705467 hasAuthorship W2567705467A5027575595 @default.
• W2567705467 hasAuthorship W2567705467A5028845635 @default.
• W2567705467 hasAuthorship W2567705467A5035354255 @default.
• W2567705467 hasAuthorship W2567705467A5046097970 @default.
• W2567705467 hasAuthorship W2567705467A5069999714 @default.
• W2567705467 hasAuthorship W2567705467A5089428686 @default.
• W2567705467 hasAuthorship W2567705467A5090435894 @default.
• W2567705467 hasConcept C109246011 @default.
• W2567705467 hasConcept C126322002 @default.
• W2567705467 hasConcept C181199279 @default.
• W2567705467 hasConcept C203014093 @default.
• W2567705467 hasConcept C2776476023 @default.
• W2567705467 hasConcept C2776694085 @default.
• W2567705467 hasConcept C2776755627 @default.
• W2567705467 hasConcept C2777866208 @default.
• W2567705467 hasConcept C2777938653 @default.
• W2567705467 hasConcept C2778461978 @default.
• W2567705467 hasConcept C2779263901 @default.
• W2567705467 hasConcept C2779338263 @default.
• W2567705467 hasConcept C2780252810 @default.
• W2567705467 hasConcept C2780653079 @default.
• W2567705467 hasConcept C2780790343 @default.
• W2567705467 hasConcept C2781413609 @default.
• W2567705467 hasConcept C55493867 @default.
• W2567705467 hasConcept C71924100 @default.
• W2567705467 hasConcept C86803240 @default.
• W2567705467 hasConcept C90924648 @default.
• W2567705467 hasConceptScore W2567705467C109246011 @default.
• W2567705467 hasConceptScore W2567705467C126322002 @default.
• W2567705467 hasConceptScore W2567705467C181199279 @default.
• W2567705467 hasConceptScore W2567705467C203014093 @default.
• W2567705467 hasConceptScore W2567705467C2776476023 @default.
• W2567705467 hasConceptScore W2567705467C2776694085 @default.
• W2567705467 hasConceptScore W2567705467C2776755627 @default.
• W2567705467 hasConceptScore W2567705467C2777866208 @default.
• W2567705467 hasConceptScore W2567705467C2777938653 @default.
• W2567705467 hasConceptScore W2567705467C2778461978 @default.
• W2567705467 hasConceptScore W2567705467C2779263901 @default.
• W2567705467 hasConceptScore W2567705467C2779338263 @default.
• W2567705467 hasConceptScore W2567705467C2780252810 @default.
• W2567705467 hasConceptScore W2567705467C2780653079 @default.
• W2567705467 hasConceptScore W2567705467C2780790343 @default.
• W2567705467 hasConceptScore W2567705467C2781413609 @default.
• W2567705467 hasConceptScore W2567705467C55493867 @default.
• W2567705467 hasConceptScore W2567705467C71924100 @default.
• W2567705467 hasConceptScore W2567705467C86803240 @default.
• W2567705467 hasConceptScore W2567705467C90924648 @default.
• W2567705467 hasLocation W25677054671 @default.
• W2567705467 hasOpenAccess W2567705467 @default.
• W2567705467 hasPrimaryLocation W25677054671 @default.
• W2567705467 hasRelatedWork W2035355653 @default.
• W2567705467 hasRelatedWork W203548035 @default.
• W2567705467 hasRelatedWork W2066910302 @default.
• W2567705467 hasRelatedWork W2078083587 @default.
• W2567705467 hasRelatedWork W2094803237 @default.
• W2567705467 hasRelatedWork W2134309110 @default.
• W2567705467 hasRelatedWork W2399276072 @default.
• W2567705467 hasRelatedWork W2417419749 @default.
• W2567705467 hasRelatedWork W2557262035 @default.
• W2567705467 hasRelatedWork W2945681833 @default.
• W2567705467 isParatext "false" @default.
• W2567705467 isRetracted "false" @default.
• W2567705467 magId "2567705467" @default.
• W2567705467 workType "article" @default.